Figure 3 | Scientific Reports

Figure 3

From: Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium

Figure 3

Forest plots of effect size and direction for tagSNPs from TRICL-ILCCO consortium. PTPN2 rs2847297 P combined = 0.004 in all individuals; P combined = 0.052 in overall adenocarcinoma individuals; P combined = 0.002 in overall squamous cell carcinoma individuals; P combined = 0.042 in overall ever smoking individuals; P combined = 0.465 in overall never smoking individuals (A); PTPN2 rs2847282P combined = 0.009 in all individuals; P combined = 0.114 in overall adenocarcinoma individuals; P combined = 0.016 in overall squamous cell carcinoma individuals; P combined = 0.066 in overall ever smoking individuals; P combined = 0.960 in overall never smoking individuals (B); Each box and horizontal line represent the OR point estimate and 95% CI derived from the additive model. The area of each box is proportional to the statistical weight of the study. Diamonds represent the ORs obtained from the combined analysis with 95% confidence intervals indicated by their widths. The meta-analysis includes eight GWAS studies [the Institute of Cancer Research (ICR) GWAS, the MD Anderson Cancer Center (MDACC) GWAS, the International Agency for Research on Cancer (IARC) GWAS, the National Cancer Institute (NCI) GWAS, the Lunenfeld-Tanenbaum Research Institute (Toronto) GWAS, German Lung Cancer Study (GLC) GWAS, Harvard Lung Cancer Study (Harvard) GWAS, Icelandic Lung Cancer Study (deCODE) GWAS]. NCI GWAS includes four sub-studies: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II Nutrition Cohort (CPS-II), the Environment and Genetics in Lung Cancer Etiology (EAGLE), and the Prostate, Lung, Colon, Ovary Screening Trial (PLCO).

Back to article page